Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MeRmaiD 1 adjuvant durvalumab plus platinum chemotherapy in resected MRD-positive NSCLC
NL-OMON54167Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + standard-of-care platinum-based chemotherapy with Placebo + standard-of-care platinum-based chemotherapy (2 arms). Primary endpoint: Disease-free survival in MRD-positive patients. Started Dec 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54167.